Additionally, patients with EGFR-mutant NSCLC who were first treated with a combination therapy using apatinib and gefitinib demonstrated prolonged PFS inclinations, indicating that the therapy was a reasonable treatment (Zhang et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.